Berenberg maintains Buy rating on ATAI Life Sciences (ATAI) with $12 price target, citing exceptional progress, strong pipeline momentum, and upcoming Phase 3 trials for psychedelic treatments.
JPMorgan raises Kodiak Sciences rating to Overweight with $24 price target, citing reduced risk for KSI-101 drug treating eye inflammation and swelling.
Clinical trial results show Inhibrx’s Ozekibart significantly improves survival measures in advanced chondrosarcoma, where no approved options exist, and demonstrates encouraging high response rates in colorectal cancer and Ewing sarcoma.
West Pharmaceuticals (WST) raises its 2025 outlook after strong demand for self-injection devices drives revenue and profit above expectations.
Innate Pharma got a "Buy" rating & $8 target. Its cancer drug IPH4502 targets a huge $1.5 billion bladder cancer market.
Morgan Stanley, Cantor Fitzgerald, and BTIG raise Viking Therapeutics (VKTX) price targets to $102-$125, citing accelerated obesity trials and upcoming FDA meeting for oral treatment.
